Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 734 results for diabet*

  1. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA294

  2. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

    Technology appraisal guidance
    Published
    23 July 2014
    View recommendations

    Sections for TA316

  3. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA412

  4. Aflibercept for untreated diabetic macular oedema [TSID10621]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Dasiglucagon for treating severe hypoglycaemia caused by type 1 diabetes in people under 6 years [TSID12255]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Digital flexor tenotomy for diabetic foot

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]

    Awaiting development Reference number: GID-TA11377 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  10. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]

    Awaiting development Reference number: GID-TA11065 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  14. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  15. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development Reference number: GID-TA11373 Expected publication date: TBC

    Technology appraisal guidance
    In development